Clinical Trials Logo

Migraine Disorders clinical trials

View clinical trials related to Migraine Disorders.

Filter by:

NCT ID: NCT02590939 Completed - Migraine Clinical Trials

Acute Treatment of Migraine With e-TNS

ACME
Start date: February 1, 2016
Phase: N/A
Study type: Interventional

The main objective of this study is to assess the efficacy of the Cefaly® device as an acute treatment of migraine attack in adult patients. The patients will be applied either an active or placebo external neurostimulation for 1 hour during a migraine attack, and will report the pain on a visual analog scale before and after the treatment.

NCT ID: NCT02583581 Recruiting - Migraine Clinical Trials

Evaluation of Use of Brain Activity Monitoring for Prediction of Migraine Attacks

Start date: October 2015
Phase: N/A
Study type: Interventional

This study evaluates the use of brain activity monitoring for prediction of migraine attacks in an expected time scale of 12-48 hours prior to the migraine attack.

NCT ID: NCT02582996 Suspended - Migraine Clinical Trials

Cefalium® Compared to Tylenol® in the Treatment of Migraine Attacks

Start date: April 2020
Phase: Phase 3
Study type: Interventional

National clinical trials, phase III, randomized, open, parallel, study of superiority, in which three hundred thirty-six (336) participants of both sexes, aged between 18 and 65 years will be randomly allocated to one of two treatment groups. The Group 01 will use Cefalium® and group 02 will use Tylenol®.

NCT ID: NCT02580968 Completed - Migraine Clinical Trials

Study of Key Electro-acupuncture Technique on Migraine

Start date: March 2015
Phase: N/A
Study type: Interventional

A random controlled trail to evaluate the efficacy of migraine standard electroacupuncture formula, and to analysis the regulation of the intensity-effects and to observe the peripheral NO, CGRP and NF-кB expression level of migraine patients after electroacupuncture treatment.

NCT ID: NCT02578719 Withdrawn - Migraine Disorders Clinical Trials

Greater Occipital Nerve (GON) Block Effectivity in the Treatment of Chronic Migraine: 6 Months Follow up

GON
Start date: July 2016
Phase: Phase 4
Study type: Interventional

This study evaluates effectiveness of greater occipital nerve blocks with bupivacaine compared to placebo in chronic migraine patients.

NCT ID: NCT02571049 Completed - Clinical trials for Rapidly Escalating Migraine

Pilot Study of Two Different Strengths of DFN-11 Injection for Rapidly Escalating Migraine

Start date: September 2015
Phase: Phase 2
Study type: Interventional

Pilot study to compare the efficacy and safety of two strengths of injections of subcutaneous DFN-11 in subjects with rapidly escalating migraine headaches.

NCT ID: NCT02570633 Completed - Migraine Clinical Trials

Ginger Capsules for the Prophylactic Treatment of Migraine

Start date: April 2015
Phase: N/A
Study type: Interventional

The main objective of the study is to evaluate ginger efficacy as an prophylactic treatment of migraine.

NCT ID: NCT02569853 Completed - Episodic Migraine Clinical Trials

DFN-11 Injection in Episodic Migraine With or Without Aura

RESTOR
Start date: September 21, 2015
Phase: Phase 3
Study type: Interventional

Safety and Efficacy of DFN-11 in patients with episodic migraines with or without aura.

NCT ID: NCT02568644 Completed - Migraine Clinical Trials

Ginger Capsules for the Acute Treatment of Migraine Attacks

Start date: July 2014
Phase: N/A
Study type: Interventional

The main objective of the study was to evaluate ginger efficacy as an adjuvant to ketoprofen for the treatment of headache and other symptoms related with migraine attacks.

NCT ID: NCT02565186 Completed - Migraine Disorders Clinical Trials

An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine

GLADIATOR
Start date: October 7, 2015
Phase: Phase 3
Study type: Interventional

This is a prospective, randomized, open-label study in subjects with migraine who have completed the Phase 3 studies, COL MIG 301/LAHJ (NCT02439320) or COL MIG-302/LAHK (NCT02605174) or for a subset of lasmiditan-naïve subjects with migraine. The study is designed to evaluate the safety and tolerability of long-term intermittent use of lasmiditan 100 mg and of lasmiditan 200 mg, as the first dose and as a second dose, for the acute treatment of migraine. Long term efficacy will also be evaluated.